Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
This tiny addition is what inhibits bacterial growth, allowing you to draw from the vial multiple times for your research without fear of contamination
We supply the very popular vitamin B12 shot to help you towards your health and wellbeing goals
Vitamin B12 shots are ideal for individuals with a B12 deficiency, those experiencing fatigue or low energy, vegans and vegetarians, and anyone seeking an immune or metabolic boost
doi: 10.1182/blood.V128.22.3618.3618 28
We treat patients of all ages, from pediatric to adult care, under one roof
